Vivitrex®, an Injectable, Extended-Release Formulation of Naltrexone, Provides Pharmacokinetic and Pharmacodynamic Evidence of Efficacy for 1 Month in Rats-Reference-Cited by-同舟云学术

Vivitrex®, an Injectable, Extended-Release Formulation of Naltrexone, Provides Pharmacokinetic and Pharmacodynamic Evidence of Efficacy for 1 Month in Rats

Published:2003-06-20 Issue:11 Volume:28 Page:1973-1982
ISSN:0893-133X
Container-title:Neuropsychopharmacology
language:en
Short-container-title:Neuropsychopharmacol

Author:

Bartus Raymond T,Emerich Dwaine F,Hotz Joyce,Blaustein Marc,Dean Reginald L,Perdomo Brigido,Basile Anthony S

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Pharmacology

Link

http://www.nature.com/articles/1300274.pdf

Reference55 articles.

1. Altshuler HL, Phillips PE, Feinhandler DA (1980). Alteration of ethanol self-administration by naltrexone. Life Sci 26: 679–688.

2. Bardo MT, Bhatnagar RK, Gebhart GF (1982). Differential effects of chronic morphine and naloxone on opiate receptors, monoamines and morphine-induced behaviors in preweanling rats. Brain Res 255: 139–147.

3. Boyle AE, Stewart RB, Macenski MJ, Spiga R, Johnson BA, Meisch RA (1998). Effects of acute and chronic doses of naltrexone on ethanol self-administration in rhesus monkeys. Alcohol Clin Exp Res 22: 359–366.

4. Capone T, Brahen L, Condren R, Kordal N, Melchionda R, Peterson M (1986). Retention and outcome in a narcotic antagonist treatment program. J Clin Psychol 42: 825–833.

5. Castelli MP, Melis M, Mameli M, Fadda P, Diaz G, Gessa GL (1997). Chronic morphine and naltrexone fail to modify mu-opioid receptor mRNA levels in the rat brain. Brain Res Mol Brain Res 45: 149–153.

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bioabsorbable, subcutaneous naltrexone implants mitigate fentanyl‐induced respiratory depression at 3 months—A pilot study in male canines;Physiological Reports;2024-08

2. Neuroprotective effects of naltrexone in a mouse model of post-traumatic seizures;Scientific Reports;2024-06-12

3. Flavonoids-based nanomedicines for the treatment of liver fibrosis: A recent progress;Journal of Drug Delivery Science and Technology;2024-03

4. Fentanyl‐induced respiratory depression in rodents is inhibited by bioabsorbable, subcutaneous naltrexone implants at 3.5 months;Addiction Biology;2023-10-27

5. Neuroprotective Effects of Naltrexone in a Mouse Model of Post-Traumatic Epilepsy;2023-10-06